128 related articles for article (PubMed ID: 6282486)
21. [Efficacy of modified retroperitoneal lymph node dissection for testicular nonseminomatous germ cell tumors].
Liu ZW; Zhou FJ; Han H; Qin ZK; Yu SL; Li YH; Ye YL; Teng XY
Ai Zheng; 2008 Dec; 27(12):1302-6. PubMed ID: 19079998
[TBL] [Abstract][Full Text] [Related]
22. Long-term followup results of 1 cycle of adjuvant bleomycin, etoposide and cisplatin chemotherapy for high risk clinical stage I nonseminomatous germ cell tumors of the testis.
Westermann DH; Schefer H; Thalmann GN; Karamitopoulou-Diamantis E; Fey MF; Studer UE
J Urol; 2008 Jan; 179(1):163-6. PubMed ID: 18001800
[TBL] [Abstract][Full Text] [Related]
23. Salvage chemotherapy with paclitaxel, ifosfamide, and cisplatin (TIP) in relapsed or cisplatin-refractory germ cell tumors.
Park S; Lee S; Lee J; Park SH; Park JO; Kang WK; Park YS; Lim HY
Onkologie; 2011; 34(8-9):416-20. PubMed ID: 21934340
[TBL] [Abstract][Full Text] [Related]
24. High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors.
Einhorn LH; Williams SD; Chamness A; Brames MJ; Perkins SM; Abonour R
N Engl J Med; 2007 Jul; 357(4):340-8. PubMed ID: 17652649
[TBL] [Abstract][Full Text] [Related]
25. Phase II trial with etoposide (VP16) plus ifosfamide plus high-dose cisplatin (VIhP regimen) in refractory germ cell tumors.
Droz JP; Ribrag V; Ghosn M; Guimares J; Theodore C; Azab M; Ostronoff M; Mahjoubi M; Moran A; Pico J
Prog Clin Biol Res; 1989; 303():739-47. PubMed ID: 2550949
[No Abstract] [Full Text] [Related]
26. In vivo resistance towards anthracyclines, etoposide, and cis-diamminedichloroplatinum(II).
Seeber S; Osieka R; Schmidt CG; Achterrath W; Crooke ST
Cancer Res; 1982 Nov; 42(11):4719-25. PubMed ID: 6889912
[TBL] [Abstract][Full Text] [Related]
27. [VM-26 and VP-16 salvage therapy for refractory germinal testicular cancers].
Miki T; Tomooka Y; Yoshimura K; Maeda O; Saiki S; Kinouchi T; Kuroda M; Usami M; Kotake T
Nihon Hinyokika Gakkai Zasshi; 1989 Nov; 80(11):1609-16. PubMed ID: 2593435
[TBL] [Abstract][Full Text] [Related]
28. VP-16-213 salvage therapy for refractory germinal neoplasms.
Williams SD; Einhorn LH; Greco FA; Oldham R; Fletcher R
Cancer; 1980 Nov; 46(10):2154-8. PubMed ID: 6159062
[TBL] [Abstract][Full Text] [Related]
29. Cisplatin and etoposide salvage therapy and resection of the residual tumor in pretreated germ cell testicular cancer.
Pizzocaro G; Pasi M; Salvioni R; Zanoni F; Milani A; Piva L
Cancer; 1985 Nov; 56(10):2399-403. PubMed ID: 2412681
[TBL] [Abstract][Full Text] [Related]
30. Late relapse of testicular cancer: Recurrence after 24 years and treatment with chemotherapy alone.
Akar E; Tural D; Arslan D; Başsorgun Cİ; Yıldız Ö
J Cancer Res Ther; 2015; 11(3):661. PubMed ID: 26458676
[TBL] [Abstract][Full Text] [Related]
31. The importance of the dose of etoposide in the initial treatment of metastatic germ cell tumors and advances in management of patients that relapse.
Marwaha S; Venner PM; North SA
Can J Urol; 2007 Oct; 14(5):3692-6. PubMed ID: 17949524
[TBL] [Abstract][Full Text] [Related]
32. Effective salvage chemotherapy with etoposide, dactinomycin, and methotrexate in refractory germ cell cancer. Australasian Germ Cell Trial Group.
Levi JA; Thomson D; Harvey V; Gill G; Raghavan D; Tattersall M; Snyder R; Burns I; Sandeman T; Byrne M
J Clin Oncol; 1990 Jan; 8(1):27-32. PubMed ID: 2153192
[TBL] [Abstract][Full Text] [Related]
33. Adjuvant chemotherapy and follow-up for recurrences in localized testicular cancer.
Boulos S; Mazhar D; Warren AY; Wong HH
Future Oncol; 2017 May; 13(11):947-950. PubMed ID: 28481147
[No Abstract] [Full Text] [Related]
34. Etoposide and cisplatin salvage chemotherapy for small cell lung cancer.
Lopez JA; Mann J; Grapski RT; Nassif E; Vannicola P; Krikorian JG; Finkel H
Cancer Treat Rep; 1985 Apr; 69(4):369-71. PubMed ID: 2986833
[TBL] [Abstract][Full Text] [Related]
35. Adjuvant Etoposide Plus Cisplatin for Patients With Pathologic Stage II Nonseminomatous Germ Cell Tumors: Is This the Preferred Option?
Einhorn LH; Adra N; Hanna N; Nichols C
J Clin Oncol; 2020 Sep; 38(26):3073-3074. PubMed ID: 32634334
[No Abstract] [Full Text] [Related]
36. Population-based study of treatment guided by tumor marker decline in patients with metastatic nonseminomatous germ cell tumor: a report from the Swedish-Norwegian Testicular Cancer Group.
Olofsson SE; Tandstad T; Jerkeman M; Dahl O; Ståhl O; Klepp O; Bremnes RM; Cohn-Cedermark G; Langberg CW; Laurell A; Solberg A; Stierner U; Wahlqvist R; Wijkström H; Anderson H; Cavallin-Ståhl E
J Clin Oncol; 2011 May; 29(15):2032-9. PubMed ID: 21482994
[TBL] [Abstract][Full Text] [Related]
37. Etoposide and very high dose cisplatin: salvage therapy for patients with advanced germ cell neoplasms.
Trump DL; Hortvet L
Cancer Treat Rep; 1985 Mar; 69(3):259-61. PubMed ID: 2983893
[TBL] [Abstract][Full Text] [Related]
38. MACC (methotrexate, doxorubicin, cyclophosphamide and lomustine) versus cis-platinum and etoposide in the treatment of advanced non-small cell lung cancer.
Buccheri G; Ferrigno D; Curcio A; Vola F; Mattalia E
Chemioterapia; 1986 Feb; 5(1):53-7. PubMed ID: 3955784
[TBL] [Abstract][Full Text] [Related]
39. Recent advances in management of patients with platinum-refractory testicular germ cell tumors.
Kollmannsberger C; Nichols C; Bokemeyer C
Cancer; 2006 Mar; 106(6):1217-26. PubMed ID: 16463389
[TBL] [Abstract][Full Text] [Related]
40. Regional deep hyperthermia for salvage treatment of children and adolescents with refractory or recurrent non-testicular malignant germ-cell tumours: an open-label, non-randomised, single-institution, phase 2 study.
Wessalowski R; Schneider DT; Mils O; Friemann V; Kyrillopoulou O; Schaper J; Matuschek C; Rothe K; Leuschner I; Willers R; Schönberger S; Göbel U; Calaminus G;
Lancet Oncol; 2013 Aug; 14(9):843-52. PubMed ID: 23823158
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
